21:48 25/05/2015 Pfizer Inc. (PFE) Closes 0.23% Down on the Day for May 25
Pfizer Inc. (PFE) Closes 0.23% Down on the Day for May 25
Equities.com - 14 hours ago
Pfizer Inc. currently has a total float of 6.16 billion shares and moves 23.92 million a day, on average. The stock opened at $34.32 on May 25 and traded between a low of $34.23 and a high of $34.49.

13:56 23/05/2015 Driven By Pfizer Inc. And Novartis AG (ADR), Global Breast Cancer Drug Sales ...
Driven By Pfizer Inc. And Novartis AG (ADR), Global Breast Cancer Drug Sales ...
Bidness ETC - May 23, 2015
Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) accounted for almost 70% of all breast cancer drug sales in 2014, while it is expected that Pfizer Inc. (NYSE:PFE) will be the key growth driver for 24% of sales in 2020 with its star breast cancer drug, Ibrance.

13:00 22/05/2015 Pfizer Inc. Mega-Merger Talk: The Speculated Targets
Pfizer Inc. Mega-Merger Talk: The Speculated Targets
Bidness ETC - May 22, 2015
Pfizer Inc. (NYSE:PFE) has made it clear that it plans to make a large and strategic acquisition this year. The largest drug maker in the US has developed a reputation for itself, demonstrating time and again that inorganic growth is just as important ...
Speculations at Peak over Pfizer Inc.'s (NYSE:PFE) Potential Targets for Merger - WallStreet.org
Could M&A Boost Pfizer More? Jefferies Thinks So - Benzinga

22:33 21/05/2015 All Eyes on Pfizer as Shareholders Await the Mega-Deal: Real M&A
All Eyes on Pfizer as Shareholders Await the Mega-Deal: Real M&A
Bloomberg - May 21, 2015
Pfizer Inc. built itself into a $212 billion behemoth by spending more money on acquisitions than any other drugmaker in the world.

13:00 21/05/2015 Pfizer Inc.-GlaxoSmithKline Merger Talk: Deutsche Bank Speculates “PfizerKline”
Pfizer Inc.-GlaxoSmithKline Merger Talk: Deutsche Bank Speculates “PfizerKline”
Bidness ETC - May 21, 2015
Rumors have already been crossing wires that Pfizer Inc. (NYSE:PFE) might be interested in a takeover of its UK-based rival GlaxoSmithKline plc (ADR) (NYSE:GSK).
Deutsche Bank claims Pfizer Inc. (NYSE:PFE) Would Benefit From Glaxo Buyout - USMarketsDaily (blog)
How a "PfizerKline" would impact the Triangle - Triangle Business Journal

16:22 20/05/2015 Pfizer Inc. To See Boosting Revenues On New Drugs Growth Through 2020
Pfizer Inc. To See Boosting Revenues On New Drugs Growth Through 2020
Bidness ETC - May 20, 2015
Pfizer Inc. (NYSE:PFE) the world's largest drug manufacturer by sales value, can generate higher long term revenues through the accelerated growth of its new drugs, over the next five years.

15:37 20/05/2015 Trade of the Day: Pfizer (PFE)
Trade of the Day: Pfizer (PFE)
Investorplace.com - May 20, 2015
Pfizer Inc. (PFE) dropped a bit after lowering its 2015 guidance as part of its latest earnings release on April 28, but it looks like investors are starting to move back into the stock as it bounces up off of the up-trending support level that was ...

13:56 13/05/2015 Better Dividend Stock: Pfizer, Inc. or GlaxoSmithKline plc?
Better Dividend Stock: Pfizer, Inc. or GlaxoSmithKline plc?
Motley Fool - May 13, 2015
Dividend stocks are undoubtedly powerful investing vehicles that can greatly amplify gains over a long period of time. That said, it's no easy feat to pick the right dividend stocks for your portfolio.

13:00 06/05/2015 2 Under-the-Radar Updates Pfizer Inc.'s Shareholders Need to Know About
2 Under-the-Radar Updates Pfizer Inc.'s Shareholders Need to Know About
Motley Fool - May 6, 2015
Pfizer (NYSE: PFE ) is a mind-bogglingly large pharmaceutical company. As such, its quarterly updates tend to focus almost exclusively on high-profile products like the pneumococcal conjugate vaccine Prevnar 13, or clinical candidates such as its ...

12:03 02/05/2015 Could This Dark Horse Be Pfizer Inc.'s Next Major Acquisition?
Could This Dark Horse Be Pfizer Inc.'s Next Major Acquisition?
Motley Fool - May 2, 2015
Given that buyouts can quickly change the complexion of a company, as well as its forward-looking prospects, I think it's definitely worthwhile to consider possible buyout scenarios.
Pfizer is unnamed bidder for Swedish rare disease firm Orphan Biovitrum - domain-B